These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27510959)

  • 1. A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
    Yang J; Yu F; Liu H; An H; Xiong R; Huang D
    Sci Rep; 2016 Aug; 6():31344. PubMed ID: 27510959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
    Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
    Nezu T; Koga M; Kimura K; Shiokawa Y; Nakagawara J; Furui E; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Naganuma M; Minematsu K; Toyoda K
    Neurology; 2010 Aug; 75(6):555-61. PubMed ID: 20697108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
    Huang YH; Zhuo ST; Chen YF; Li MM; Lin YY; Yang ML; Chen ZJ; Cai RW
    Chin Med J (Engl); 2013; 126(24):4685-90. PubMed ID: 24342312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis.
    Sobesky J; Frackowiak M; Zaro Weber O; Hahn M; Möller-Hartmann W; Rudolf J; Neveling M; Grond M; Schmulling S; Jacobs A; Heiss WD
    Cerebrovasc Dis; 2007; 24(1):56-65. PubMed ID: 17519545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild stroke: safety and outcome in patients receiving thrombolysis.
    Logallo N; Kvistad CE; Naess H; Waje-Andreassen U; Thomassen L
    Acta Neurol Scand Suppl; 2014; (198):37-40. PubMed ID: 24588505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
    Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):1033-1040. PubMed ID: 29221968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
    Liu M; Pan Y; Zhou L; Wang Y
    Neurol Res; 2019 May; 41(5):473-479. PubMed ID: 30822264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of a new modified intravenous recombinant tissue plasminogen activator (rt-PA) regimen in Chinese patients with acute ischemic stroke: A descriptive retrospective cohort study with subgroup-analysis of different rt-PA dose.
    Luo Y; Li J; Huang L; Liu X; Zhang B; Lin J; Jiang A; Zhao J
    J Clin Neurosci; 2022 Jul; 101():244-251. PubMed ID: 35653882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.